Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program
0
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: Despite the high efficacy of direct-acting antivirals (DAAs), approximately 1–3% of hepatitis C virus (HCV) patients fail to achieve a sustained virological response. We conducted a nationwide study to investigate risk factors associated with DAA treatment failure. Machine-learning algorithms have been applied to discriminate subjects who may fail to respond to DAA therapy. Methods: We analyzed the Taiwan HCV Registry Program database to explore predictors of DAA failure in HCV patients. Fifty-five host and virological features were assessed using multivariate logistic regression, decision tree, random forest, eXtreme Gradient Boosting (XGBoost), and artificial neural network. The primary outcome was undetectable HCV RNA at 12 weeks after the end of treatment. Results: The training (n=23,955) and validation (n=10,346) datasets had similar baseline demographics, with an overall DAA failure rate of 1.6% (n=538). Multivariate logistic regression analysis revealed that liver cirrhosis, hepatocellular carcinoma, poor DAA adherence, and higher hemoglobin A1c were significantly associated with virological failure. XGBoost outperformed the other algorithms and logistic regression models, with an area under the receiver operating characteristic curve of 1.000 in the training dataset and 0.803 in the validation dataset. The top five predictors of treatment failure were HCV RNA, body mass index, α-fetoprotein, platelets, and FIB-4 index. The accuracy, sensitivity, specificity, positive predictive value, and negative predictive value of the XGBoost model (cutoff value=0.5) were 99.5%, 69.7%, 99.9%, 97.4%, and 99.5%, respectively, for the entire dataset. Conclusions: Machine learning algorithms effectively provide risk stratification for DAA failure and additional information on the factors associated with DAA failure.
Abstract
Background/Aims: Despite the high efficacy of direct-acting antivirals (DAAs), approximately 1–3% of hepatitis C virus (HCV) patients fail to achieve a sustained virological response. We conducted a nationwide study to investigate risk factors associated with DAA treatment failure. Machine-learning algorithms have been applied to discriminate subjects who may fail to respond to DAA therapy. Methods: We analyzed the Taiwan HCV Registry Program database to explore predictors of DAA failure in HCV patients. Fifty-five host and virological features were assessed using multivariate logistic regression, decision tree, random forest, eXtreme Gradient Boosting (XGBoost), and artificial neural network. The primary outcome was undetectable HCV RNA at 12 weeks after the end of treatment. Results: The training (n=23,955) and validation (n=10,346) datasets had similar baseline demographics, with an overall DAA failure rate of 1.6% (n=538). Multivariate logistic regression analysis revealed that liver cirrhosis, hepatocellular carcinoma, poor DAA adherence, and higher hemoglobin A1c were significantly associated with virological failure. XGBoost outperformed the other algorithms and logistic regression models, with an area under the receiver operating characteristic curve of 1.000 in the training dataset and 0.803 in the validation dataset. The top five predictors of treatment failure were HCV RNA, body mass index, α-fetoprotein, platelets, and FIB-4 index. The accuracy, sensitivity, specificity, positive predictive value, and negative predictive value of the XGBoost model (cutoff value=0.5) were 99.5%, 69.7%, 99.9%, 97.4%, and 99.5%, respectively, for the entire dataset. Conclusions: Machine learning algorithms effectively provide risk stratification for DAA failure and additional information on the factors associated with DAA failure.
참고문헌 (42)
- Hayes CN, "Road to elimination of HCV : Clinical challenges in HCV management", Liver Int, 42, pp.1935~1944 (2022)
- Hong CM, "Drug resistance profile and clinical features for hepatitis C patients experiencing DAA failure in Taiwan", Viruses, 13, pp.2294~ (2021)
- Solitano V, "Management and treatment of hepatitis C : Are there still unsolved problems and unique populations?", Viruses, 13, pp.1048~ (2021)
- Huang CF, "Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy", Clin Mol Hepatol, 26, pp.251~260 (2020)
- Hassabis D, "Neuroscience-inspired artificial intelligence", Neuron, 95, pp.245~258 (2017)
- Su TH, "Artificial intelligence in precision medicine in hepatology", J Gastroenterol Hepatol, 36, pp.569~580 (2021)
- Le Berre C, "Application of artificial intelligence to gastroenterology and hepatology", Gastroenterology, 158, pp.76~94 (2020)
- Topol EJ, "High-performance medicine : the convergence of human and artificial intelligence", Nat Med, 25, pp.44~56 (2019)
- Chen CY, "Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C : A real-world nationwide hepatitis C virus registry programme in Taiwan", Liver Int, 41, pp.1265~1277 (2021)
- Yu ML, "2020Taiwan consensus statement on the management of hepatitis C : part(I)general population", J Formos Med Assoc, 119, pp.1019~1040 (2020)
- Yu ML, "2020Taiwan consensus statement on the management of hepatitis C : Part(II)special populations", J Formos Med Assoc, 119, pp.1135~1157 (2020)
- Petrazzini BO, "Evaluation of different approaches for missing data imputation on features associated to genomic data", BioData Min, 14, pp.44~ (2021)
- Dankers FJWM, "Fundamentals of clinical data science", pp.101~120 (2019), Springer
- DeLong ER, "Comparing the areas under two or more correlated receiver operating characteristic curves : a nonparametric approach", Biometrics, 44, pp.837~845 (1988)
- Belle V, "Principles and practice of explainable machine learning", Front Big Data, 4, pp.688969~ (2021)
- Davila JA, "Diabetes increases the risk of hepatocellular carcinoma in the United States : a population based case control study", Gut, 54, pp.533~539 (2005)
- Tsai PC, "Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan", J Hepatol, 78, pp.281~292 (2023)
- Charlton M, "Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease", Gastroenterology, 149, pp.649~659 (2015)
- Bhaskaran K, "Association of BMI with overall and cause-specific mortality : a population-based cohort study of 3·6 million adults in the UK", Lancet Diabetes Endocrinol, 6, pp.944~953 (2018)
- Global BMI Mortality Collaboration, "Body-mass index and all-cause mortality : individual-participant-data meta-analysis of 239 prospective studies in four continents", Lancet, 388, pp.776~786 (2016)
- Chen WM, "High viral load predicts virologic failure in chronic genotype 2hepatitis C virus-infected patients receiving glecaprevir", pibrentasvir therapy, 2020, pp.119, 1593~1600
- Salmon D, "HCV viral load at baseline and at week 4 of telaprevir", boceprevir based triple therapies are associated with virological outcome in HIV, J Clin Virol, pp.2015, 73[DOI]
- Park H, "Machine learning algorithms for predicting direct-acting antiviral treatment failure in chronic hepatitis C : An HCV-TARGET analysis", Hepatology, 76, pp.483~491 (2022)
- Ji F, "Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma : A systematic review and meta-analysis", J Hepatol, 71, pp.473~485 (2019)
- Ogawa E, "Hepatitis C virus cure rates are reduced in patients with active but not inactive hepatocellular carcinoma : A practice implication", Clin Infect Dis, 71, pp.2840~2848 (2020)
- Huang CF, "Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study", BMJ Open, 9, pp.e026703~ (2019)
- Konjeti VR, "Interaction between hepatocellular carcinoma and hepatitis C eradication with direct-acting antiviral therapy", Curr Treat Options Gastroenterol, 16, pp.203~214 (2018)
- Sachdeva M, "Immunology of hepatocellular carcinoma", World J Hepatol, 7, pp.2080~2090 (2015)
- Dang H, "Cure with interferon-free direct-acting antiviral is associated with increased survival in patients with hepatitis C virus-related hepatocellular carcinoma from both East and West", Hepatology, 71, pp.1910~1922 (2020)
- Lee SW, "Direct-acting antiviral therapy for hepatitis C virus in patients with BCLC stage B", C hepatocellular carcinoma, 2022, pp.14, 2316~
- Huang CF, "Direct-acting antivirals in East Asian hepatitis C patients : realworld experience from the REAL-C Consortium", Hepatol Int, 13, pp.587~598 (2019)
- Curry MP, "Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis", N Engl J Med, 373, pp.2618~2628 (2015)
- Modi AA, "Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1hepatitis C cirrhosis", Liver Transpl, 22, pp.281~286 (2016)
- Belli LS, "ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients", J Hepatol, 67, pp.585~602 (2017)
- Bunchorntavakul C, "HCV therapy in decompensated cirrhosis before or after liver transplantation : A paradoxical quandary", Am J Gastroenterol, 113, pp.449~452 (2018)
- Ekpanyapong S, "Hepatitis C virus therapy in advanced liver disease : Outcomes and challenges", United European Gastroenterol J, 7, pp.642~650 (2019)
- Mayr A, "The evolution of boosting algorithms. From machine learning to statistical modelling", Methods Inf Med, 53, pp.419~427 (2014)
- Ilboudo WEL, "Robust stochastic gradient descent with student-t distribution based first-order momentum", IEEE Trans Neural Netw Learn Syst, 33, pp.1324~1337 (2022)
- Bussmann N, "Explainable AI in fintech risk management", Front Artif Intell, 3, pp.26~ (2020)
- Calderaro J, "Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma", J Hepatol, 76, pp.1348~1361 (2022)
- Sarrazin C, "Treatment failure with DAA therapy : Importance of resistance", J Hepatol, 74, pp.1472~1482 (2021)
- Ridruejo E, "Hepatitis C virus treatment failure : Clinical utility for testing resistanceassociated substitutions", World J Hepatol, 13, pp.1069~1078 (2021)